← All trials
NCT06359912
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2024
- Primary completion
- Apr 30, 2025
- Completion date
- Jul 31, 2025
- First posted
- Apr 11, 2024
- Last posted
- Apr 11, 2024
- Enrollment
- 27
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Allife Medical Science and Technology Co., Ltd.Lead sponsor
- Jiao Tong UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.